unknown
Stage
About
Barricade Therapeutics is a clinical-stage oncology company developing BT-1501, a first-in-class oral small-molecule therapy targeting the genetic drivers of colorectal cancer progression to provide a precision treatment alternative.
Explore Barricade Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.